The Senate overwhelmingly passed legislation to reauthorize key funding for the Food and Drug Administration, with the measure including key amendments to tackle high drug prices and access to experimental drugs.

The Thursday vote of 94-1 sends the legislation on the FDA’s user fee program to President Trump, who is expected to sign it, according to a White House aide.